HER2-Directed T-Cell Receptor-Mimicking Antibody: A "Me Too" or an Example of Novel Antitumor Aggressive Mimicry?

被引：1
作者：
Bianchini, Giampaolo [1 ]
Gianni, Luca [1 ]
机构：
[1] Ist Sci San Raffaele, Dept Med Oncol, I-20132 Milan, Italy
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 03期
关键词：
METASTATIC BREAST-CANCER; MONOCLONAL-ANTIBODY; OPEN-LABEL; TRASTUZUMAB; PLUS; PERTUZUMAB; CHEMOTHERAPY; LAPATINIB; TRIAL; MULTICENTER;
D O I：
10.1093/jnci/djs636
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：161 / 163
页数：3
相关论文
共 30 条
  • [1] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue
    Van Cutsem, Eric
    Feyereislova, Andrea
    Chung, Hyun C.
    Shen, Lin
    Sawaki, Akira
    Lordick, Florian
    Ohtsu, Atsushi
    Omuro, Yasushi
    Satoh, Taroh
    Aprile, Giuseppe
    Kulikov, Evgeny
    Hill, Julie
    Lehle, Michaela
    Ruschoff, Josef
    Kang, Yoon-Koo
    [J]. LANCET, 2010, 376 (9742) : 687 - 697
  • [2] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
    Baselga, Jose
    Cortes, Javier
    Kim, Sung-Bae
    Im, Seock-Ah
    Hegg, Roberto
    Im, Young-Hyuck
    Roman, Laslo
    Pedrini, Jose Luiz
    Pienkowski, Tadeusz
    Knott, Adam
    Clark, Emma
    Benyunes, Mark C.
    Ross, Graham
    Swain, Sandra M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) : 109 - 119
  • [3] A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
    Bertotti, Andrea
    Migliardi, Giorgia
    Galimi, Francesco
    Sassi, Francesco
    Torti, Davide
    Isella, Claudio
    Cora, Davide
    Di Nicolantonio, Federica
    Buscarino, Michela
    Petti, Consalvo
    Ribero, Dario
    Russolillo, Nadia
    Muratore, Andrea
    Massucco, Paolo
    Pisacane, Alberto
    Molinaro, Luca
    Valtorta, Emanuele
    Sartore-Bianchi, Andrea
    Risio, Mauro
    Capussotti, Lorenzo
    Gambacorta, Marcello
    Siena, Salvatore
    Medico, Enzo
    Sapino, Anna
    Marsoni, Silvia
    Comoglio, Paolo M.
    Bardelli, Alberto
    Trusolino, Livio
    [J]. CANCER DISCOVERY, 2011, 1 (06) : 508 - 523
  • [4] Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
    Blackwell, Kimberly L.
    Burstein, Harold J.
    Storniolo, Anna Maria
    Rugo, Hope S.
    Sledge, George
    Aktan, Gursel
    Ellis, Catherine
    Florance, Allison
    Vukelja, Svetislava
    Bischoff, Joachim
    Baselga, Jose
    O'Shaughnessy, Joyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2585 - 2592
  • [5] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
    Burstein, Harold J.
    Sun, Yan
    Dirix, Luc Y.
    Jiang, Zefei
    Paridaens, Robert
    Tan, Antoinette R.
    Awada, Ahmad
    Ranade, Anantbhushan
    Jiao, Shunchang
    Schwartz, Gary
    Abbas, Richat
    Powell, Christine
    Turnbull, Kathleen
    Vermette, Jennifer
    Zacharchuk, Charles
    Badwe, Rajendra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307
  • [6] High frequency of altered HLA class I phenotypes in invasive breast carcinomas
    Cabrera, T
    Fernandez, MA
    Sierra, A
    Garrido, A
    Herruzo, A
    Escobedo, A
    Fabra, A
    Garrido, F
    [J]. HUMAN IMMUNOLOGY, 1996, 50 (02) : 127 - 134
  • [7] Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Cortes, Javier
    Fumoleau, Pierre
    Bianchi, Giulia Valeria
    Petrella, Teresa M.
    Gelmon, Karen
    Pivot, Xavier
    Verma, Shailendra
    Albanell, Joan
    Conte, Pierfranco
    Lluch, Ana
    Salvagni, Stefania
    Servent, Veronique
    Gianni, Luca
    Scaltriti, Maurizio
    Ross, Graham A.
    Dixon, Joanna
    Szado, Tania
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1594 - 1600
  • [8] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
    Di Leo, Angelo
    Gomez, Henry L.
    Aziz, Zeba
    Zvirbule, Zanete
    Bines, Jose
    Arbushites, Michael C.
    Guerrera, Stephanie F.
    Koehler, Maria
    Oliva, Cristina
    Stein, Steven H.
    Williams, Lisa S.
    Dering, Judy
    Finn, Richard S.
    Press, Michael F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552
  • [9] ERBB-2 IS A POTENT ONCOGENE WHEN OVEREXPRESSED IN NIH/3T3 CELLS
    DIFIORE, PP
    PIERCE, JH
    KRAUS, MH
    SEGATTO, O
    KING, CR
    AARONSON, SA
    [J]. SCIENCE, 1987, 237 (4811) : 178 - 182
  • [10] Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Geyer, Charles E.
    Forster, John
    Lindquist, Deborah
    Chan, Stephen
    Romieu, C. Gilles
    Pienkowski, Tadeusz
    Jagiello-Gruszfeld, Agnieszka
    Crown, John
    Chan, Arlene
    Kaufman, Bella
    Skarlos, Dimosthenis
    Campone, Mario
    Davidson, Neville
    Berger, Mark
    Oliva, Cristina
    Rubin, Stephen D.
    Stein, Steven
    Cameron, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) : 2733 - 2743
123